MCM
BCYC

Manchester Capital Management’s Bicycle Therapeutics BCYC Stock Holding History

Manchester Capital Management’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-590
Closed -$4.57K – 1354
2025
Q3 		$4.57K Hold
590
– – ﹤0.01% 968
2025
Q2 		$4.1K Hold
590
– – ﹤0.01% 931
2025
Q1 		$5.01K Hold
590
– – ﹤0.01% 901
2024
Q4 		$8.26K Hold
590
– – ﹤0.01% 828
2024
Q3 		$13.4K Buy
590
+140
+31% +$3.23K ﹤0.01% 755
2024
Q2 		$9.11K Buy
+450
New +$10.2K ﹤0.01% 772

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
GP
GSK plc London $599M AUM
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Manchester Capital Management's BCYC Position: Q4 2025 in Review

Manchester Capital Management sold out of Bicycle Therapeutics (BCYC) in Q4 2025, closing a stake of 590 shares — an estimated $4.57K sold.

Manchester Capital Management first reported a position in BCYC in Q2 2024 and held it in 6 quarters. The position peaked at $13.4K in Q3 2024. 109 funds tracked by Wall St. Rank hold BCYC as of Q4 2025.

  • Manchester Capital Management reported no remaining Bicycle Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Manchester Capital Management sold 590 Bicycle Therapeutics shares in Q4 2025, an estimated $4.57K.
  • Manchester Capital Management first reported a position in Bicycle Therapeutics in Q2 2024 and held it in 6 quarters.
  • Manchester Capital Management's Bicycle Therapeutics position peaked at $13.4K in Q3 2024.
  • 109 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q4 2025.

Based on Manchester Capital Management's 13F filing for Q4 2025, filed 11 Feb 2026.